Loading...
•
Mar 31, 2022
Generation Bio Q1 2022 Earnings Report
Generation Bio optimized its cell-targeted lipid nanoparticle (ctLNP) delivery system and reported its Q1 2022 financial results.
Key Takeaways
Generation Bio reported a net loss of $35.0 million for the first quarter of 2022. The company's cash and cash equivalents were $337.0 million as of March 31, 2022, which is expected to fund operations into 2024. The company is focused on optimizing its ctLNP delivery system for liver, retina, and vaccine applications.
Cash and cash equivalents were $337.0 million as of March 31, 2022.
The company's cash position is expected to fund its operating plan into 2024.
Research and development expenses were $25.6 million for the quarter ended March 31, 2022.
Net loss was $35.0 million, or $0.61 basic and diluted net loss per share, for the quarter ended March 31, 2022.
Generation Bio
Generation Bio
Forward Guidance
The company continues to believe that its cash position will fund its operating plan into 2024.